source
- Legend Biotech CEO Ying Huang resigns abruptly, board taps interim leaderLegend Biotech announced that its chief executive, Dr. Ying Huang, has stepped down unexpectedly, leaving the role vacant. Huang, who moved from chief financial officer to CEO in 2020 after a cust…
- Processa Pharma acquires Vidya Therapeutics, gaining oral BTK inhibitor VT-7208Processa Pharmaceuticals announced an all‑stock acquisition of Vidya Therapeutics, a Florida biotech developing an oral BTK inhibitor called VT‑7208. VT‑7208 is being positioned as a next‑generati…